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Interpreting changes over time in small-area variation in cancer survival, in light of changes 
in cancer incidence, aids understanding progress in cancer control, yet few space-time 
analyses have considered both measures. Bayesian space-time hierarchical models were applied to 
Queensland Cancer Registry data to examine geographical changes in cancer incidence and relative 
survival over time for the five most common cancers (colorectal, melanoma, lung, breast, prostate) 
diagnosed during 1997-2004 and 2005-2012 across 516 Queensland residential small-areas. Large 
variation in both cancer incidence and survival was observed. Survival improvements were 
fairly consistent across the state, although small for lung cancer. Incidence changes varied by 
location and cancer type, ranging from lung and colorectal cancers remaining relatively 
constant over time, to prostate cancer dramatically increasing across the entire state. 
Reducing disparities in cancer-related outcomes remains a health priority, and space-time 






With an estimated 14.1 million cancer cases diagnosed globally in 2012,1 the impact of 
cancer is felt worldwide. With wide variation in cancer incidence and survival not only 
between countries,1,2 but also within countries,3,4 there are important disparities depending on 
where people live. 
Quantifying and understanding the extent of small-area variation in cancer incidence and 
survival is becoming increasingly important, with government and other policy makers 
needing to make evidence-based decisions on resource allocation and planning interventions 
to address any known disparities. Consistent with this, an increasing number of small-area 
cancer atlases have been published, including those in Australia,5-7 USA8 and the UK.9   
There is great variation in the statistical approaches used in these Atlases. These methods 
range from direct estimation of area-specific age-standardised incidence rates5 through to 
modelling approaches incorporating smoothing such as Poisson kriging,10 empirical Bayes11 
or fully Bayesian methods.7 While each method has various benefits and disadvantages, some 
form of smoothing is often preferred to reduce spurious variation associated with very small 
area-specific counts.12 
We have previously demonstrated the extent of small area variation  in incidence and survival 
across the state of Queensland, Australia for around 20 of the most commonly diagnosed 
cancers.6 This cancer atlas highlighted  the extent of the geographical variability in incidence 
across Queensland, and how the survival outcomes were poorer in many of the more remote 
areas of the state. 
However, it was unclear how these geographical patterns in cancer incidence and survival 
have changed over time. Since the ability to understand whether the spatial patterns are 
changing over time and in what direction is critical to guide efforts to reduce existing 
disparities, we have examined how the geographical variation in cancer incidence and 
survival in Queensland has changed over time for the five most commonly diagnosed 
cancers. 
2. Methods 
Ethical approval to conduct this study was obtained from the Darling Downs Hospital and 
Health Service Human Research Ethics Committee (HREC/15/QTDD/57). 
2.1 Data and Analysis 
De-identified data on all cases of colorectal (ICD-O-313 C18-C20, C218), lung (ICD-O-3 
C33-C34), melanoma (ICD-O-3 C44 M872-M879), breast (ICD-O-3 C50) and prostate (ICD-
O-3 C61) diagnosed in Queensland during 1997 to 2012 was obtained from the population-
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based Queensland Cancer Registry (QCR). All non-keratinocytic cancers diagnosed are 
notifiable by law.  
The patient’s address at diagnosis was geocoded within the QCR, and assigned to one of 516 
residential Statistical Area 2s (SA2s) based on the 2011 Australian Statistical Geography 
Standard (ASGS) boundaries.14 SA2s with an average population below 5 during 1997-2012 
were considered to be non-residential and were excluded (n=10). In 2011, the median 
population of a residential SA2 was 7996 (range:7 to 29,641). Cases with insufficient 
information to determine the SA2 at diagnosis were excluded. 
The study cohort included those diagnosed with an invasive cancer and aged 15-89 years at 
diagnosis. Cases diagnosed through death or autopsy were excluded. Year of diagnosis was 
split into two diagnostic time periods: 1997-2004 and 2005-2012. 
The QCR routinely conducts data linkage with the Australian National Death Index to 
determine the survival status of all cancer patients. Survival time (in days) was provided by 
the QCR, with follow-up of all patients to 2013. For the survival analyses, cases were 
censored at the earliest of five years from diagnosis or the specified censoring date, which 
was 31 December 2005 for the 1997-2004 cohort and 31 December 2013 for the 2005-2012 
cohort.  
As is the case for most population-based cancer survival studies, we used relative survival to 
estimate net survival. Since it compares the cohort mortality against the population mortality, 
relative survival has the advantage over cause-specific survival in not requiring cause of 
death information.15  
To calculate the SA2-specific population mortality rates, unit record file death data were 
obtained from the Australian Bureau of Statistics (ABS) (for deaths from 1997 to 2005)16 and 
the Australian Coordinating Registry (2006-2013).17 Corresponding population data for each 
SA2, 5-year age group and sex was obtained from the Australian Bureau of Statistics (ABS) 
for 1997-2013. Concordance files provided by the ABS were used to adjust all the 
geographical information to the 2011 ASGS SA2 boundaries. To account for the low 
numbers of deaths in some SA2, single year age, sex and year categories, a smoothing 
process was used to increase the stability of the expected mortality. Briefly, population and 
mortality data for each SA2 were aggregated into strata comprising three time periods (1997-
2002, 2003-2008, 2009-2013), by 5-year age group (to 90+ years) and sex.  Neighbouring 
SA2s were identified based mainly on shared boundaries, although islands included nearby 
mainland areas. “Smoothed” population mortality rate estimates for specific SA2s by strata 
group were then calculated by combining the SA2-specific mortality and population with the 
corresponding data from all neighbouring areas. These smoothed estimates were then 
expanded so the same mortality rate was assigned to each single year age, single calendar 
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year, sex and SA2 within any given 5-year age group, 5-year or 6-year calendar time period, 
sex and SA2. These smoothed estimates were used in both the non-Bayesian and Bayesian 
relative survival models. 
 
2.2 Incidence models 
To examine changes in cancer incidence over time, a Bayesian space-time model based on 
that introduced by Bernardinelli et al.18 was used. A Poisson distribution:  
𝑂𝑖𝑗~Poisson(𝜃𝑖𝑗𝐸𝑖𝑗) 
forms the foundation of this model, where 𝑂𝑖𝑗 are the observed new cancer cases in 
i=1,2…516 areas and j=1,2 time periods (representing 1997-2004 and 2005-2012), 𝜃𝑖𝑗 is the 
corresponding modelled standardised incidence ratio (SIR) and 𝐸𝑖𝑗  represents the age- and 
sex-standardised expected counts. The log of the modelled SIR can then be written as: 
log(𝜃𝑖𝑗) = 𝛼 + 𝜆𝛿𝑗 + 𝑠𝑖𝛿𝑗 + 𝑢𝑖 + 𝑣𝑖 
and each of these parameters were given prior distributions. The intercept term 𝛼 and 
coefficients 𝜆 for the jth time period indicator 𝛿 have vague normal priors, 𝑢𝑖 (structured 
spatial variation) and 𝑠𝑖 (the differential trend) are assumed to follow an intrinsic conditional 
autogressive (CAR) prior with neighbours assigned based largely on geographically adjacent 
boundaries (since islands included the closest mainland areas as neighbours), and 𝑣𝑖 
represents unstructured spatial variation, with a vague normal distribution for each of 𝑖 areas. 
Additional details on the prior distributions are provided in Supplementary Table S1.   
Since the expected counts were standardised by age and sex, these variables were not 
included in this model. 
 
2.3 Relative survival models 
Recently, we introduced a Bayesian space-time flexible parametric relative survival model.19 
This approach had many advantages over Poisson-piecewise based models, including the 
feasibility of including individual-level data, time-varying components and complex 
interactions.20  
Consider that the dth individual (d=1,…D) with covariate 𝑥𝑑 lives in area i (represented as 
i[d], similar to Gelman and Hill21), then the space-time relative survival model can be written 
as: 
ln(− ln 𝑅𝑖𝑗(𝑡)) = ln(Λ(𝑡)) =  ln(Λ0(𝑡)) + x𝑑β + 𝜆𝛿𝑗 + 𝑠𝑖[𝑑]𝛿𝑗 + 𝑢𝑖[𝑑] + 𝑣𝑖[𝑑] 
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where 𝑅𝑖𝑗(𝑡) is the relative survival function for the ith area (i=1,…516), and jth time period 
(1,2 representing cases diagnosed in 1997-2004 and 2005-2012, respectively), Λ(t) is the 
cumulative excess hazard, Λ0(t) is the cumulative baseline excess hazard (the cumulative 
excess hazard when all covariates are 0) and β= [𝛽1, … , 𝛽𝐾] and represents the vector of 
coefficients relating to covariates x𝑑 = [x𝑑1, … , x𝑑𝐾]. The indicator variable for the jth time 
period is 𝛿𝑗, the overall temporal change is represented by 𝜆, and 𝑠𝑖[𝑑] is the difference in 
excess mortality between the overall time change and the ith area. 
Note that the cumulative excess hazard is composed of two terms,  
Λ(𝑡) = H(t) − H∗(t) 
where H(t) is the overall cumulative hazard, based on all deaths within the cohort, and H∗(t) 
is the cumulative expected hazard, obtained from the population mortality estimates.  
This model is based on the Weibull distribution, but the cumulative excess baseline hazard 
Λ0(t) is flexibly modelled using restricted cubic splines as a function of log time. The spline 
component enables flexible parametric models to fit the data better than parametric models.22 
Provided at least one interior knot is specified, the spline includes a constant term (𝛾0), a 
parameter with a linear function of log time (𝛾1), and, for each subsequent interior knot 
m=1,…,M, a basis function (𝑧𝑚(𝑡)) with associated parameter(𝛾𝑚+1). The model can thus be 
written as: 
ln(− ln 𝑅𝑖𝑗(𝑡)) = 𝛾0 + 𝛾1 ln(𝑡) . . , +𝛾𝑀+1𝑧𝑀(𝑡) + x𝑑β + 𝜆𝛿𝑗 + 𝑠𝑖[𝑑]𝛿𝑗 + 𝑢𝑖[𝑑] + 𝑣𝑖[𝑑] 
The covariates included in the model were age (centred continuous spline terms) and sex 
(males, females) for lung, colorectal, and melanoma.  
 
Each model parameter was given a prior distribution, with vague normal distributions 
assumed for 𝛾𝑚, β, 𝜆 and 𝑣𝑖[𝑑], while 𝑢𝑖[𝑑] and 𝑠𝑖[𝑑] were each given an intrinsic CAR prior with 
neighbours again based largely on shared boundaries (see Supplementary Table S1 for details on 
prior distributions).   
 
2.4 Model assessment 
All incidence and survival models were run as single chain Markov chain Monte Carlo 
(MCMC) in WinBUGS v1.4.3 interfaced with Stata v14.2. Running a single chain for an 
extended time adequately enables convergence assessment, and has theoretical justification.23  
Incidence and survival models discarded the first 70,000 iterations and monitored a further 
50,000 iterations, keeping every 10th iteration to reduce the autocorrelation. 
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Convergence of the MCMC estimates was assessed graphically via trace plots and segment 
histograms for a subsample of areas with low populations (𝑠𝑖 , 𝑢𝑖 , 𝑣𝑖), as well as all 𝛼, β, 𝜆 and 
𝛾𝑚 terms. Autocorrelation was also graphically assessed. The Geweke diagnostic
24 was used 
to monitor convergence on all parameters, and is calculated as the difference between the 
means for the first 10% of iterations and the final 50% of iterations, divided by the 
asymptotic standard error of the difference. An estimate with a Geweke p-value below 0.01 
was considered unlikely to have converged. Convergence diagnostics for colorectal cancer 
are available in Supplementary Figures S1 to S2. 
Relative survival models were first run in Stata using the stpm2 command with just the fixed 
effects (𝛾𝑚, β, 𝜆) to enable determination of model components, before running the full 
Bayesian model in WinBUGS. Since these initial models required population mortality data, 
the ‘smoothing’ was carried out prior to running the full Bayesian model. Likelihood ratio-
tests and plots of predicted hazard components were used to determine which variables to 
include as time-varying components. The preferred number of knots for the restricted cubic 
splines (for centred continuous age, the baseline hazard, and any time-varying components) 
was selected based on Bayesian information criterion (BIC) values, as well as plotting the 
predicted hazard function. Details on the final model specifications are shown in 
Supplementary Table S2. Estimates for the 𝛾𝑚, β, and 𝜆 terms from WinBUGS were checked 
against the estimates using the corresponding survival model in Stata and found to be similar 
for all five types of cancer. 
 
Sensitivity analyses considered two vague distributions on the hyperprior variance 
component 𝜎2 for 𝑣𝑖[𝑑], 𝑢𝑖[𝑑] and 𝑠𝑖[𝑑] by comparing their impact on the final estimates. 
Models were run for the following options: 




i. CAR distribution on 𝑠𝑖 and 𝑠𝑖[𝑑] 
ii. Vague normal distribution on 𝑠𝑖  and 𝑠𝑖[𝑑] 
2. Uniform distribution (minimum, maximum) on the standard deviation, 
𝜎~U(0 ,20) 
i. CAR distribution on 𝑠𝑖 and 𝑠𝑖[𝑑] 
ii. Vague normal distribution on 𝑠𝑖  and 𝑠𝑖[𝑑] 
Although similar estimates were obtained under both distributions, option 1.i with the CAR 
distribution on the differential trend component was selected since it improved convergence 





Maps were generated using MapInfo Pro v15.0. As the majority of SA2s are located in the 
urbanised south-east corner, this region is magnified on maps using an oval inset. The 
estimates used in the maps were the median of the posterior distributions calculated as 
follows: 
 SIR for 1997-2004: exp(𝛼 + 𝑢𝑖 + 𝑣𝑖) 
 SIR for 2005-2012: exp(𝛼 + 𝜆𝛿𝑗 + 𝑠𝑖𝛿𝑗 + 𝑢𝑖 + 𝑣𝑖) 
 Change in SIR between 1997-2004 and 2005-2012: exp(𝜆𝛿𝑗 + 𝑠𝑖𝛿𝑗). 
Likewise, the adjusted relative survival estimates were calculated as excess hazard ratios 
(EHRs) as follows: 
 EHR for 1997-2004: exp(𝑢𝑖[𝑑] + 𝑣𝑖[𝑑]) 
 EHR for 2005-2012: exp(𝜆𝛿𝑗 + 𝑠𝑖[𝑑]𝛿𝑗 + 𝑢𝑖[𝑑] + 𝑣𝑖[𝑑]) 
 Change in EHR between 1997-2004 and 2005-2012: exp(𝜆𝛿𝑗 + 𝑠𝑖[𝑑]𝛿𝑗) 
For the second time period of 2005-2012, the baseline reference for the SIR and EHR was the 
1997-2004 Queensland average. This meant that any of the maps with an average value (set 
to 1) had a similar incidence/excess risk of death within five years of diagnosis as the 
Queensland average during 1997-2004. 
The same five categories were used across all maps to enable meaningful comparisons 
between the maps. These were deliberately selected to be wide, to reduce the likelihood of 
detecting spurious changes. Cut-points of 10% and 30% above the average (=1) estimate 
were selected (1.1 and 1.3 respectively), while the corresponding lower cut-offs were the 
inverse of these values (0.91 and 0.77). 
The 80% credible intervals (CrIs) typically provide sufficient coverage of the posterior 
distributions generated from a well-fitting Bayesian model,25 so are generally considered to 
correspond to the standard 95% confidence intervals reported in non-Bayesian analyses. 
Graphs of the 80% CrIs with the interval shading demonstrating the mapped colour of the 
median SIR/EHR estimate for each SA2 are provided in Supplementary Figures S3-S7. The 
graphs for 2005-2012 estimates also show the median SIR/EHR estimate for each SA2 during 
1997-2004 as a grey dot, showing changes in the median estimate for each SA2. 
Maps showing ‘convincing’ changes over time were also generated, and these were based on 
the 80% credible intervals for exp(𝜆𝛿𝑗 + 𝑠𝑖𝛿𝑗) or exp(𝜆𝛿𝑗 + 𝑠𝑖[𝑑]𝛿𝑗) being above one 
(increase), below one (decrease), or, if it included one it was considered equivocal. These 
maps in Figure 2 show which areas are likely to have experienced change between the time 







During 2005-2012, there were almost 112,000 new diagnoses of the five most common 
cancers among our study cohort (Table 1). This was an increase of almost 31,000 new cases 
diagnosed compared to 1997-2004. Across total Queensland, incidence rates were lower for 
colorectal cancer in the later time period but higher for prostate cancer (Table 1). The age-
standardised incidence rates for breast, lung and melanoma remained reasonably similar over 
the two time periods, with overlapping 95% confidence intervals. These findings were also 
reflected in the overall modelled time trends, although the small increase in breast cancer 
incidence was considered convincing in the modelled results with the 80% credible interval 
not including one (Table 1). Details on all modelled parameter estimates are available in 
Supplementary Table S3. 
There was marked variation in cancer incidence across residential areas in both time periods 
for the five cancer types (Figure 1). The incidence of most cancer types was lower in the 
more rural and remote areas further away from the east coastline, particularly between 1997 
and 2004. The exception was lung cancer, in which the incidence was generally higher in 
more remote areas, although some urban areas in the south-east corner of the state also had 
higher incidence in both time periods.  
The patterns of change over time differed by cancer type and geographic location (Figures 1 
and 2).  In the majority of areas, colorectal cancer was relatively stable. Only 5 areas showed 
a convincing increase between the two time periods in colorectal cancer incidence, while 67 
areas decreased (Figure 2). While more areas changed over time for melanoma incidence (67 
areas increased, 62 areas decreased), these patterns depended on broad location with 
melanoma incidence rates tending to decrease in more remote areas, but increase in south-
eastern and coastal northern Queensland areas. There was more stability in lung cancer 
incidence rates between the two time periods, with only 15 areas showing a decrease and 13 
areas an increase. In contrast, the predominant pattern for breast (100 areas increased, 4 
decreased) and prostate cancer (477 increased, 0 decreased) was for the incidence rates to 
increase between the two time periods. Again, this pattern varied by geographic location, 
with the increase in breast cancer incidence being predominately around northern and western 
Queensland, while the increases for prostate cancer incidence were larger and more 
widespread. 
3.2 Survival 
The five-year relative survival for cancers diagnosed during 2005-2012 ranged from 16.5% 
(lung) to 94.6% (prostate) (Table 1). For all cancers except melanoma, this represented an 
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increase in survival from those diagnosed during 1997-2004. After adjustment for age and 
sex (where applicable), the increase in survival across total Queensland for all five cancers 
was statistically convincing (Table 1). Prostate cancer showed the greatest change, with the 
risk of death within 5 years almost halving, while the reduction for lung cancer (8% decrease) 
was smallest. Details on all modelled parameter estimates are available in Supplementary 
Table S3. 
For each individual cancer type diagnosed in 1997-2004, there was wide geographical 
variation in the median risk of dying from that cancer within 5 years of diagnosis (Figure 3). 
However, the pattern of geographical variation was consistent across the cancer types, with 
the excess risk of death within 5 years of diagnosis being lower in the south-east corner of the 
state, and higher in the other western and northern areas. 
Between 1997-2004 and 2005-2012, the predominant pattern was for the median survival to 
increase across most areas (Figures 2 and 3). This meant that many areas with cancers 
diagnosed during 2005-2012 had a reduced excess risk of death within 5 years of diagnosis 
(Figure 3).  
Every SA2 showed a convincingly decreased risk of death within 5 years for breast cancer, 
and almost every area for prostate and colorectal cancers (Figure 2). Even lung cancer had 
convincing decreases (albeit generally small) in 342 areas. Of these, the change ranged from 
5% to 15% lower risk of death than during 1997-2004, so many were not noticeable when 
reporting the median risk estimates in Figure 3. Melanoma likewise had widespread 
decreases across the state (Figure 3), but only 266 areas were considered to have convincing 
decreases (Figure 2).  In comparison, the large changes in prostate cancer over time, ranging 
from 28% to 60% lower excess risk of death within 5 years compared to those diagnosed 
during 1997-2004, meant that there was no inconsistency between the different maps.  
4. Discussion 
In Queensland, the risk of a cancer diagnosis or cancer-related death varies by residential 
location. This is true for all five of the most commonly diagnosed cancers, whether diagnosed 
during 1997-2004, or during 2005-2012. The general improvement in survival over most 
areas between the two time periods means that geographical disparities have remained. This 
suggests that it is not sufficient to just ensure that diagnostic and management strategies are 
equivalent across the state, rather reasons for the disparities need to be understood to develop 
geographically focused strategies to ensure that the cancer-related outcomes are equivalent 
across the state. 
Of the five cancer types examined, prostate cancer showed the greatest and most consistent 
improvement in survival across all areas of the state between the two time periods, coinciding 
with similar consistent increases in incidence. This pattern supports the hypothesis of an 
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impact of prostate specific antigen (PSA) testing, in that the subsequent overdiagnosis of 
localised prostate cancers leads to increased incidence and artificially increased survival due 
to lead-time bias. While it has been shown that the use of PSA testing is higher in capital 
cities of Australia compared to the rest of the country,26 the testing rate increased in both 
areas. However, the recent  release of guidelines recommending a reduction in the use of 
PSA27 may impact future spatial and temporal patterns. 
Breast cancer also showed large survival improvements, with incidence generally increasing, 
particularly in more remote areas. All women aged between 50-69 years were eligible for 
publicly-funded mammography screening every 2 years throughout the time period 
examined, and nationally participation remained around 55% consistently, with variation by 
remoteness (lowest participation in very remote areas, highest participation in outer regional 
areas).28 Breast cancer treatment has also improved29 and the rural mobile mammography 
services went digital in 2009.30 
Melanoma likewise showed large, albeit rather uncertain, improvements in survival, with 
incidence increasing only among certain regions in northeastern and southeastern 
Queensland, and decreasing elsewhere. As regular skin checks can assist in early detection, 
the lower diagnosis rate of melanoma in more remote areas suggests the availability of skin 
checking services might be influencing incidence patterns. It is possible the survival 
improvements are driven more by improved therapies. For advanced melanoma, there have 
been recent advances in targeted therapies and immunotherapies.31  
In contrast, the decrease in colorectal cancer incidence was observed over most areas of 
Queensland, yet survival improvements were consistent over the state. In contrast to prostate 
cancer, screening for colorectal cancer through FOBT testing is designed to detect pre-
cancerous polyps, which, if found and removed, would result in lower incidence. However, 
the participation in the national colorectal cancer screening program since it was introduced 
in 2006 has been low, particularly among remote areas,32 so it is unlikely to have impacted on 
the observed results. Targeted therapies have also become available for advanced colorectal 
cancer,33 and it is possible they may be influencing the improved survival. 
The almost negligible change in lung cancer incidence over the two time periods is likely a 
result of combing both males and females with their contrasting incidence trends.34 Survival 
improvements, although often convincing, were small in magnitude, reflecting that lung 
cancer is often diagnosed at a later stage and there have been limited improvements in 
treatment during the time periods examined.35 
Other Bayesian space-time models have been developed and applied to cancer incidence data, 
including age-period-cohort,36,37 dynamic38,39 and mixture models.40 Age-period-cohort 
models can be useful when strong cohort effects are expected, such as for lung cancer, but 
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assume minimal migration between areas. In contrast, mixture models are focused on 
detecting disparate areas which will not be smoothed over, while dynamic models are more 
useful when there are many time periods involved. In this analysis, we expected neighbouring 
regions to have similar outcomes, so did not use a model that allowed for disparate changes. 
Others have examined different forms of interactions between spatial and temporal 
components,41,42 but as we only had two time components, this was not investigated. 
However, when several time periods are available, some form of correlation across time 
should be considered. 
The choice of intervals for maps requires careful consideration, since different intervals can 
lead to different interpretation. For this reason we presented maps showing the median 
estimates for each SA2 (categorised into five groups), as well as those areas with a 
convincing difference to the Queensland average (based on 80% credible intervals). Both 
maps have different but complementary purposes. The median captures the magnitude of the 
difference, although ignores the level of uncertainty, while the statistically convincing 
changes captures areas we are confident do differ to some extent from the average, without 
quantifying the magnitude of that difference. We acknowledge that there are many other 
ways of defining and visualising the magnitude, significance and uncertainty of spatial 
estimates, and the optimal methods of presenting static and dynamic disease maps continues 
to be an active field of research.43  
Within the Bayesian framework, convergence, sensitivity and identifiability of model 
parameters need to be considered. We divided the residual component into three terms: 𝑠𝑖, 𝑢𝑖 
and 𝑣𝑖. It is recognised that spatial models are often unable to identify even two separate 
terms (𝑢𝑖 and 𝑣𝑖),
44 and given our specific interest in the differential trend component 𝑠𝑖, we 
chose to place a stronger hyperprior distribution on the variance for these three terms to aid in 
identifiability.  
Interpreting the driving factors behind geographical variation and changes in incidence and 
survival is difficult without information about tumour stage at diagnosis. Currently the 
Queensland Cancer Registry does not record stage at diagnosis for all cancers, although a 
broad measure of spread of disease is available for breast cancer45 and stage for colorectal 
cancer estimated using pathology forms.46 For consistency across cancers, the impact of stage 
was not examined in this study. However, our previous work has found that differences in 
stage at diagnosis was the key driver of poorer breast cancer survival among more remote 
areas, while for colorectal cancer, factors related to the time after diagnosis played a greater 
role in the survival disparities.20 
Other limitations included the lack of treatment information, and the substantial computation 
time involved in running the models through WinBUGS, especially for the more complex 
relative survival models which ranged from 11.5 hours for breast cancer to 20.5 hours for 
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prostate cancer on a dual CPU Quad Core Xeon E5520 computer. The use of emerging 
approximation methods, such as integrated nested Laplace approximation (INLA), is 
increasing within the spatial field, and offers much potential to reduce computation times 
although it does not have the flexibility of likelihood specification available in WinBUGS. 
 Strengths of this study include a high quality population-based cancer registry with full 
coverage of the cancers diagnosed among Queensland residents, the use of an innovative 
relative survival methodology that appropriately captures both spatial variation and temporal 
changes in that variation, and a population dispersed over areas of varying remoteness. 
In conclusion, our space-time analyses have provided unique insights into how the 
geographical patterns in cancer incidence and survival have changed over time in 
Queensland. While the improvements in survival are encouraging, the lack of reduction in the 
spatial variation between the two time periods means that cancer patients who live in specific 
geographical areas continue to experience poorer survival outcomes than those living in other 
areas. To reduce these disparities in outcomes, greater focus needs to be placed on 
understanding why these disparities occur, and then implementing appropriate interventions 
to address the barriers to equal outcomes.  
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Table 1: Cohort incidence, survival and time changes by cancer type, persons, aged 15-89 years, Queensland 
 Incidence 
  
5-year relative survival 
  
 1997-2004 2005-2012 
Modelled 
change in 




EHR [80% CrI]  N cases ASR [95% CI] N cases ASR [95% CI] RS [95% CI] RS [95% CI] 
Colorectal 17,628  63.9 [63.0,64.9] 21,953  61.2 [60.4,62.1] 0.96 [0.95, 0.97]  64.6 [63.2, 66.0] 70.2 [68.9, 71.4] 0.80 [0.77, 0.82]  
Melanoma 18,025  71.9 [70.8,72.9] 23,062  71.5 [70.5,72.4] 1.00 [0.99, 1.02] 94.7 [93.8, 95.6] 94.2 [93.4, 95.0] 0.86 [0.80, 0.93]  
Lung 12,129  43.9 [43.1,44.7] 15,624  43.2 [42.5,43.9] 0.99 [0.97, 1.00]  14.2 [13.1, 15.3] 16.5 [15.5, 17.6] 0.92 [0.90, 0.93]  
Breast (females) 16,621  127.7 [125.8,129.7] 21,583  130.1 [128.4,131.9] 1.04 [1.02, 1.05] 88.5 [87.4, 89.5] 91.0 [90.2, 91.8] 0.75 [0.71, 0.79] 
Prostate 16,711  126.5 [124.6,128.5] 29,691  171.8 [169.9,173.8] 1.34 [1.33, 1.36]  84.7 [83.1, 86.2] 94.6 [93.8, 95.4] 0.53  [0.49, 0.56]  
N=number, ASR=age-standardised rate, CI=confidence interval, CrI=credible interval, RS=relative survival, SIR=standardised incidence ratio, EHR=excess hazard ratio. 
Note than an 80% CrI is considered equivalent coverage to a 95% CI. 
Rates age-standardised to the WHO world 2000 standard population as modified by SEER. 
Relative survival is calculated using an unadjusted cohort analysis of the lifetable method. 
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Changes between 1997-2004 
and 2005-2012b  
Breast cancer, females 
   
Prostate cancer, males 
   
SIR=Standardised incidence ratio.  
The median posterior estimate is mapped. 
a. Results are in comparison to the Queensland average incidence in 1997-2004 (set to 1).  
b. Results for changes between time periods are in comparison to each individual SA2, so 1=the same incidence in that SA2 




Figure 2: Convincing changes between 1997-2004 and 2005-2012 by cancer type, 
Queensland 
Risk of diagnosis Excess risk of death within five 
years of diagnosis 
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Notes: Convincing is defined as the 80% credible interval not including one. These estimates are for the risk of 




Figure 3: Spatial variation in excess risk of death within five years of diagnosis by cancer 
type, Queensland, 1997-2012 
1997-2004a 
 
2005-2012a  Changes between 1997-2004 
and 2005-2012b 
Colorectal cancer, persons 
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2005-2012a  Changes between 1997-2004 
and 2005-2012b 
Breast cancer, females 
   
Prostate cancer, males 
   
EHR=Excess hazard ratio.  
The median posterior estimate is mapped. 
a. Results are in comparison to the Queensland average excess risk of death in 1997-2004 (set to 1).  
b. Results for changes between time periods are in comparison to each individual SA2, so 1=the same excess risk of death in 
that SA2 during 1997-2004.  
